Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MNKD vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPT Captures Overall Composite Edge (52.4 HOLD vs 38.4 SELL), While MNKD Leads 5–1 on Growth & Valuation Pillars

RAPT Overall Winner 6-Pillar Tally: MNKD 5 – 1 RAPT Matrix Metrics: MNKD 4 – 6 RAPT

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Mannkind Corporation (MNKD) on higher Unified Composite conviction (52.4/100 HOLD vs. 38.4/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality), while MNKD wins 5–1 across the 6-pillar growth and valuation breakdown. MNKD trades at $3.94 (26.2x Forward P/E, -3.4% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. MNKD 38.4/100 SELL) and -0.02β · 2% Vol risk profile, whereas MNKD leads top-line expansion (+24.0% YoY revenue growth, 4.39x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNKD vs RAPT
MNKD NASDAQ
Mannkind Corporation
Pharmaceutical Preparations
$3.94
-4.48% 1D
Market Cap $1.3B
TTM Revenue $413M
Forward P/E 26.2x
Beta / 30D Vol 1.30β · 50% Vol
Unified Composite Score
38.4 / 100 SELL
Tech 8.0 Fund 38.0 Flow 72.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.7 · SMA20: $3.66 · SMA50: $3.57
RAPT NASDAQ Head-to-Head Winner
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (MNKD 5 – 1 RAPT)

Columns: Metric · MNKD · RAPT
1. Valuation Multiples MNKD
Forward P/E 26.2x N/M
Trailing P/E 32.3x N/M
PEG Ratio 4.39x N/M
EV / Revenue 3.9x N/M
2. Growth & Scale MNKD
Revenue Growth (YoY) +24.0% -100.0%
Earnings Growth (YoY) -34.9% +0.0%
TTM Revenue (USD) $413M N/A
Market Cap $1.3B $1.7B
3. Profitability & Quality RAPT
Gross Margin 75.8% N/A
Operating Margin -3.4% 0.0%
Net Profit Margin -18.1% 0.0%
Return on Equity (ROE) 0.0% -85.4%
4. Balance Sheet & Cash Flow MNKD
Cash Generation (TTM) -$78M N/A
Cash Flow Margin -19.0% N/A
Net Cash / Leverage $289M Net Debt $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNKD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 66.9% (7th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat MNKD
OpEx & R&D Intensity 79.2% of Rev ($327M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNKD (4) vs RAPT (6)
Institutional Metric MNKD RAPT Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.7B Larger Scale RAPT
Trailing P/E Ratio
Valuation
32.3x N/M Lower Multiple MNKD
Forward P/E Ratio
Valuation
26.2x N/M Lower Multiple MNKD
Revenue Growth (YoY)
Growth
+24.0% -100.0% Higher Growth MNKD
Operating Margin (TTM)
Profitability
-3.4% 0.0% Higher Margin RAPT
Net Profit Margin
Profitability
-18.1% 0.0% Higher Margin RAPT
Return on Equity (ROE)
Capital Efficiency
0.0% -85.4% Higher ROE MNKD
52-Week Range Position
Momentum
40% ($2–$7) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
1.30β · 50% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
38.4 / 100 (SELL) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
$413M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
4.39x PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$78M ($289M Net Debt) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +48.26 pp
MNKD: -47.58% · RAPT: +0.68%
3M Horizon RAPT +118.03 pp
MNKD: -43.59% · RAPT: +74.44%
6M Horizon RAPT +141.97 pp
MNKD: -40.02% · RAPT: +101.95%
1Y Horizon RAPT +141.97 pp
MNKD: -40.02% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNKD vs RAPT. Trailing 12-month operating profitability (MNKD -3.4% vs RAPT 0.0%) and valuation multiples (MNKD 26.2x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MNKD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$413M
Gross Margin75.8%
Op. Margin-3.4%
ROE / Fwd P/E0.0% · 26.2x
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNKD CONSOLIDATION
95d in phase · OBV ACCUMULATION
Current IV 66.9%
IV Percentile 7th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MNKD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNKD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -3.4% operating margin.
OpEx & R&D Reinvestment 79.2% of Rev ($327M)
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNKD vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Mannkind Corporation (MNKD) on higher Unified Composite conviction (52.4/100 HOLD vs. 38.4/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality), while MNKD wins 5–1 across the 6-pillar growth and valuation breakdown. MNKD trades at $3.94 (26.2x Forward P/E, -3.4% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. MNKD 38.4/100 SELL) and -0.02β · 2% Vol risk profile, whereas MNKD leads top-line expansion (+24.0% YoY revenue growth, 4.39x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

MNKD leads the Growth & Scale pillar: MNKD posts +24.0% YoY revenue growth and -34.9% YoY earnings growth on $413M TTM revenue (75.8% gross margin, -3.4% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MNKD generates $413M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, MNKD deploys 79.2% of Rev ($327M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

MNKD screens cheaper on headline valuation multiples. MNKD trades at 26.2x Forward P/E, 32.3x Trailing P/E, 4.39x PEG, and 3.9x EV/Revenue (-19.0% FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNKD (0.0% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MNKD carries 66.9% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.30β · 50% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.